Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lamivudine + stavudine
- Development stage
- Unknown
- Lead developer
- Strides Pharma Science
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A fixed-dose combination of two nucleoside reverse transcriptase inhibitors used in the treatment of HIV-1 infection. Both drugs act by terminating the growth of the DNA chain and inhibiting the reverse transcriptase of HIV.
02
Targets
Human immunodeficiency virus type 1 reverse transcriptasePOLG (Mitochondrial DNA polymerase gamma)
Beyond the preview
Go deeper on lamivudine + stavudine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lamivudine + stavudine.